Clinical Trial Update: Effect of Rosiglitazone on ADMA in Critical Illness [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rosiglitazone on ADMA levels in patients with critical illness and multiple organ failure. The trial status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness
• Multiple Organ Failure

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Critical Illness, Multiple Organ Failure | Phase 3 | Status: UNKNOWN